ACTU vs EFX · $49.0M cap vs P/E 54, rev $5.68B
Actuate Therapeutics, Inc. Common stock (ACTU) versus Equifax Inc (EFX) — a side-by-side from cached financials, not a winner call.
Actuate Therapeutics, Inc. Common stock (ACTU) is a biotechnology company listed on NASDAQ.
Equifax Inc (EFX) is a consulting services company listed on US.
ACTU does not have a complete income-statement cache yet.
Latest reported EFX revenue for 2024-12-31 was $5.68B. Net income was $607.3M. Revenue was up 7.9% from 2023-12-31 to 2024-12-31. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
ACTU currently screens at market cap $49.0M. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
Not investment advice. Open the ACTU and EFX stock pages for the full models.
Not investment advice.